title: Primary biliary cirrhosis exacerbated by a course of acute hepatitis C and subsequent interferon therapy.
authors.forename: M
authors.initials: M
authors.lastname: Yoshikawa
authors.forename: M
authors.initials: M
authors.lastname: Mimura
authors.forename: A
authors.initials: A
authors.lastname: Shiroi
authors.forename: H
authors.initials: H
authors.lastname: Kojima
authors.forename: H
authors.initials: H
authors.lastname: Fukui
authors.forename: Y
authors.initials: Y
authors.lastname: Sugimoto
authors.forename: T
authors.initials: T
authors.lastname: Mochi
mesh_terms: D000208:Acute Disease; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001706:Biopsy; D018562:Disease Transmission, Infectious; D005260:Female; D016174:Hepacivirus / Q000235:genetics; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy* / Q000635:transmission; D006801:Humans; D007279:Injections, Subcutaneous; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects*; D008105:Liver Cirrhosis, Biliary / Q000201:enzymology / Q000209:etiology* / Q000473:pathology; D008875:Middle Aged; D016602:Needlestick Injuries / Q000150:complications; D012367:RNA, Viral / Q000032:analysis; D011994:Recombinant Proteins; D000637:Transaminases / Q000097:blood
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins; D000637:Transaminases